CTIC CTI BioPharma Corp.

0.95
0  0%
Previous Close 0.95
Open 0.92
Price To Book 2.96
Market Cap 69,893,332
Shares 73,922,086
Volume 82,705
Short Ratio
Av. Daily Volume 249,906
Stock charts supplied by TradingView

NewsSee all news

  1. CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15

  2. CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results

    SEATTLE, March 12, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019. "In the latter half of 2019 and beginning

  3. CTI BioPharma Announces Closing of Rights Offering

    SEATTLE, March 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering").  At the closing, CTI BioPharma sold and

  4. CTI BioPharma Announces Commencement of Rights Offering

    SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering").

  5. CTI BioPharma Announces Proposed Rights Offering

    SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released July 9. 2018. Primary endpoint not met.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3 Spleen Volume Reduction (SVR) data due by the end of 2021.
Pacritinib - PACIFICA
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15

  2. CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results

    SEATTLE, March 12, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019. "In the latter half of 2019 and beginning

  3. CTI BioPharma Announces Closing of Rights Offering

    SEATTLE, March 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering").  At the closing, CTI BioPharma sold and

  4. CTI BioPharma Announces Commencement of Rights Offering

    SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering").

  5. CTI BioPharma Announces Proposed Rights Offering

    SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors

  6. CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia

    SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency"), CTI has reached

  7. CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting

    SEATTLE, Dec. 9, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from the PAC203 Phase 2

  8. CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

    SEATTLE, Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American

  9. CTI BioPharma Reports Third Quarter 2019 Financial Results

    SEATTLE, Nov. 4, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019. "We advanced our pacritinib development

  10. CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

    SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment